Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
and a good volume too. Long wait, eh?
g.p.
nice bounce here geo.
Perhaps if the people at Tissera Inc. receive any funding from the U.S government, they will acknowledge it with some sort of press release. That's the least they should do to alert shareholders that they are still working and researching stem cell technology.
President Obama's budget is over 600 pages, and somewhere in that document there is money earmarked for Stem Cell Research.
Getting ahold of a copy of that budget would be a good way to verify. Not sure if specfic companies would be mentioned as to the allocation amounts set aside for research. I think the budget is a public record and can be obtained.
Shareholders should not give up here.
Perhaps contacting our local Senator or Congress person and asking questions?
Tough to verify. The 2 named employees, (older Doctors doing the research), are in Israel. Since April, TSSR is not on the OTCBB (re filings, etc...).
Hope the rumor turns out real but I'm not counting on it.
g.p.
Some rumors surfacing about the administration finally providing Tissera Inc. and other Stem Cell research companies with much needed funding to continue Stem Cell research as President Obama had promised during his campainge.
Someting that needs to be verified.
Yes, they are too silent.
Listed as having 2 employees. (As far as I know, these are the two Doctors doing the organ transplant therapy research.)
also:December 11, 2008, the number of shares outstanding of the registrant's Common Stock, $0.0001 par value (the only class of voting stock), was 45,591,809. AND
There has been no significant news since January 2008.
g.p.
They could also get some dollars from the feds to help finance their activites in Stemcell research. That's a good possibilty. They are way to silent, that's for sure.
You never know with this type of company. The research could payoff eventually.
Big problem is lack of update and also the difficulty to get any information.
I'm holding and watching but expecting the worst eventually.
Oh well...
g.p.
its breathing .... barely ... 0.015
Not that I know of. I have to presume that they've got another year of research.
Remember that the $1.01 high came that day in early April when, between 10AM and noon, we saw a few trades well above that .03.
Consider .06 as the year high.
Used to have a website but something happened in Israel; it's a totally different, unrelated website.
Don't make this one a priority.
g.p.
any news soon, this company still breathing ?
Likely, nothing.
over 250,000 shares traded at .001 before that final trade at .005.
Recent volumes are higher than average, but then, this is trading as a subpenny and no news from the two people involved in Tissera.
g.p.
my ameritrade gain/loss report for yesterday was showing a pps of 0.018 and todays's close is 0.005. what's up?
Could have been. Stockwatch still shows $1.01 as year high but its price chart only shows .03 as April 3.
Not 5 years for me but over 2 years...
g.p.
April 3rd was a pump and dump, obviously someone knows something out there and dumped all their stock real quick. I bought in around 2004 2005 and it's plumitted since then, hope something happens soon, 5 years is a long time to wait.
Weeks have passed. It did not take long to get back to sub penny status!
Still wondering what happened, that day for such a weird activity.
g.p.
So we had a little more activity than usual but not that much.
The new $1.01 high (that one day with weird trades,) does look better than the otherwise .07 year high...
g.p.
Looks like it might have been errors. Stockwatch shows nearly 750K shares traded Friday BUT with a high of only .03 and a low of .003. Gone the .10, .55, .85 and $1.01.
However, the others I've checked still show year high of $1.01. The saga continues...
g.p.
That was quite a wild ride, this morning.
The year's high-low will look very different, comes Monday.
Will it affect the volume? the price?
BTW, does anyone have a clue to what caused those transactions?
g.p.
well luckily for me im playing with the houses money at this point
I've been carrying this one for a couple of years. No news, not much happening.
However, I think the research renewal, in Israel, is usually extended each year, in April.
Can only wait and see. Wonder if these were real. two trades at $1.01 for 600 shares, trades at .75, .55, even .10.
we may never know! Anyway, it's back, as you say, at .01
GLTY
g.p.
yes, exactly what happened today? now at .01 but as high as 1.01
Can you believe the activity, just before 11AM?
Didn't last long! Back at .02.
Anyone knows what happened?
g.p.
The 'E' is out. Tissera is back as TSSR.
Not much has changed. Quotes now OK.
Do read the annual report.
g.p.
Something's afoot #3
Excitement at minimum. Following the 1,433% gain, TSSRE somewhat fell back.
The B/A is around .006 - .02 Still much much better than the old .0015.
Note: TSSRE to get real quotes (TSSR will get you what we see on IHub quote or 'defunct' comment.) The E is for delayed reporting. Tissera was a couple months late Figure the E to stay for a while.
g.p.
Something's afoot... cont.
Going to www.tissera.com will give some explanation. SEC year end has been submitted as of today; their usual agreement runs to April '09.
So, finally, some news...
g.p.
Something's might be afoot, Watson.
Tissera, trading now under TSSRE, has been languishing as a sub-penny, closing, last week at .0015.
Opened at .0069, then one trade at .023. Quite a jump!
B/A .023 - .04. My Broker doesn't show any news, so far.
A pleasant surprise if it lasts.
g.p.
Nothing has changed since your April post. Of course, the share price is close to subpenny and it remains a good tax deduction. I'll wait for 2009 Tax time. I figure another year won't make much difference.
GLTY
g.p.
I concur. I think this stock is not that closely held as before and perhaps more shares are on the market.
I do not have too much here and my average is in the teens.
Yes, it looks like a main candidate for income tax deductions.
Good Luck.
g.p.
i got back in and am losing as well. this junk got pumped and the owners i think could care less about the stock price - i think they cashed out big time and are not doing anything to make it move. i'm just holding until i need the capital gain loss - i would never invest another dime in this outfit and i have told all my friends the same.
You tripled your money, then.
Have you been just watching since you sold?
I'm in and losing, so far, never giving up, but that could come. We're lucky, here if there is one yearly release stating another year extension.
You could be right.
g.p.
this stock is one of the worst dogs i have ever owned. i bought at $1.90 about four years ago and got out at $6.10 then watched it pump to $8.90 that same day and sink like a rock ever since. the company has produced nothing to interest investors that i have seen. pure hype and junk - a stinkin pink, imo.
might be..came up on a scan of mine..gonna put it on the sleeperzz board.
mo
Bd
A ray of hope? Volume and high of .10, today.
After that.04, recently, this .075 closing is satisfactory.
g.p.
I know it's a Special week end for Americans but hitting .08 was not very festive! No news doesn't seem to be good news, here.
g.p.
thanks for the info bro
Here's something from BusinessWire:
"Tissera Reports Significant Milestone Achievement in Its Large Animal Diabetic Model Studies
HERZLIYA, Israel, Aug 08, 2007 (BUSINESS WIRE) -- (BusinessWire)
Tissera, Inc. (OTCBB:TSSR) reports the achievement of a significant milestone in its ongoing large animal diabetic model experiments of pancreatic xenotransplantation, designed for the future treatment of insulin-dependent (type I) diabetes mellitus.
Based on the previously reported positive results obtained in pancreatic transplantation experiments in normal non human primates, Tissera's sponsored research team at the Weizmann Institute of Science (http://www.weizmann.ac.il/) has moved forward to investigate in diabetic non human primates the functional and therapeutic value of the company's approach. In these studies, non human primates are treated by an agent called streptozotocin which induces them to become diabetic and consequently dependent upon administration of exogenous insulin for the maintenance of reasonable blood sugar levels. After allowing a few weeks for stabilization, appropriately timed pig embryonic pancreatic tissue is transplanted into the diabetic primate, which is thereafter intensively and carefully followed.
In a previous press release, the company reported preliminary results showing a progressive post transplantation reduction of the insulin amounts required for maintenance of blood sugar levels, together with the demonstration of the presence of slight blood insulin levels, suggestive of endogenous insulin production. It was then mentioned that the pig origin of this insulin remained to be determined in order to unequivocally attribute its presence to production by the growing pancreatic graft.
In further experiments, this progressive post transplantation reduction of the insulin amounts required for maintenance of near normal blood sugar levels was consistently observed. By the fourth month after transplantation, the insulin dose needed to maintain near-normal blood sugar levels decreased by more than 90% in comparison with the insulin dose needed before transplantation, meaning that endogenous insulin production was predominantly responsible for blood sugar control.
The crucial question of the graft origin of this endogenous insulin was addressed by measurement of blood C-peptide, which is a peptide which splits from insulin precursor in the process of insulin formation and thus its blood levels closely reflect pancreatic insulin secretion. C-peptide levels were measured both at baseline and in response to sugar load administration which brings about a rise in blood C-peptide. The measured C-peptide was shown to be predominantly of pig origin. Those results provide a definitive proof for the pancreatic pig transplant origin of insulin presence in the diabetic primate's blood and constitute a very significant milestone achievement in the company's efforts to demonstrate the therapeutic value of its technology in the treatment of insulin dependent (type I) diabetes mellitus.
About Diabetes Mellitus
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world's population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
About Tissera
Tissera is a biotechnology company dedicated to the development of novel tissue precursor regeneration technologies for treating gene deficiencies and diseases in which organ transplantation is necessary, while minimizing the dosage of immunosuppressive drugs. Tissera obtained the license for the worldwide exclusive rights to the technology developed by Professor Yair Reisner and his team at the Weizmann Institute of Science in Israel. In this research, scientists successfully implanted in mice embryonic human and porcine organ precursor tissues, which grew into functional organs. This research was published in Nature Medicine and attracted worldwide scientific and media attention.
For more information please visit Tissera website:
www.tissera.com ..."
Still trading around .10...
g.p.
thanks for the info man. I have been in this stock for 4 months. I wanted to find out how often does the company put out Press releases as far as the progress of the company. I have 23550 shares that i got for $.14 cents so $3,297 right now at 11 cents I have 2590.50 so a total loss of 21% I will keep holding it because I am in no hurry to sell. I think if any publication or firm talks about this company we will easily get this one in the 15-18 cent range again
Did sell some around .20 and bought back around .12. That helped the average. Like you, this one is a disappointment for me. Holding for now but if I feel this one's not going anyplace, I'll not wait for .15 to pull out!
Holding,
g.p.
Yea its just frustrating; If they have bad new or good news they are still obligated to release it to the shareholders. I am so mad because the volume has gone completely down. I feel real bad for the people that loaded up on the shares when they were in the 20 cent range. I bought in the 14 cent range so if i want i can bail out. But i will hang on to it. But one thing i can guarantee if it does go back up I am getting out at 14 and never looking back
Waiting too and also about 20% down.
Aside of the one year renewall with the Weizmann Institute, announced 2 months ago, there hasn't been much. Can't find the share count but seem to remember it was up to 45M then.
The site www.tissera.com or email info@tissera.com might help. I might try soon.
From the site, a recent SEC filing originate from Richmont BC Canada. Formal addresses are still NY, NY and Tel Aviv.
Not much, eh?
g.p.
WHat is going on with this stock It has completely flat lined. I am still hopefull and holding my 24k shares that i bought at $.15 they have to release news eventually; for a company in the health industry I can't believe they have not come out with their progress.
thanks for the tip I bailed out of dkam at 1.36 i got in at 1.40 so i cut my loss. I figure with the dow crashing today gives me a lot more opportunity to get in at great prices with established companies which will rebound next week. Mrks looks great when did you get in looks like the stock is over saturated with low volume. but thanks for the tip appreciate it
Ot-kartikji dkam,i don't know if there is a good entry point,I just don't see reorders of it in the stores.I would wait to see if it drops below a buck.I don't plan on buying it.Only one stock i'm still buying MKRS. Good Luck to you.
yessss it is alive. Looks like great suppport hopefully heading to the $.20 mark
THIS IS CRAZY NO BUYS OR SELLS. ZERO VOLUME AT 12:16 ANY ONE HAVE ANY IDEA WHAT IS GOING ON???
People shorting above.15 will buy back if TSSR creeps up to .13 or more. Lower shorts may need to cover up. Unless TSSR starts to be sold short, it should not affect the share price much. Time will tell.
g.p.
It looks like the stock may start creeping upwards from this point. I am just worried that a lot of shorts will be bailing out once the stock reaches .12-.13 but i know there is a lot of money that is invested in this company. I just feel bad for the people that got in at .20 cent range before the stock plunged on the bad news on 5/29; but that is what will keep the stock from fluctuating due to those people who are in it for the long haul.
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
365
|
Created
|
10/31/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |